Last reviewed · How we verify
Pembrolizumab/Quavonlimab
Pembrolizumab/Quavonlimab is a combination of a PD-1 inhibitor and a TIGIT inhibitor, which works by blocking the PD-1 and TIGIT proteins to enhance the body's immune response against cancer cells.
Pembrolizumab/Quavonlimab is a combination of a PD-1 inhibitor and a TIGIT inhibitor, which works by blocking the PD-1 and TIGIT proteins to enhance the body's immune response against cancer cells. Used for Locally advanced or metastatic non-small cell lung cancer, Locally advanced or metastatic small cell lung cancer.
At a glance
| Generic name | Pembrolizumab/Quavonlimab |
|---|---|
| Also known as | MK-1308A |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | PD-1/TIGIT inhibitor |
| Target | PD-1, TIGIT |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pembrolizumab is a monoclonal antibody that targets the PD-1 protein, preventing it from interacting with its ligands and thereby releasing the brakes on the immune system. Quavonlimab is a monoclonal antibody that targets the TIGIT protein, which is also involved in the regulation of the immune response. By blocking these proteins, pembrolizumab/quavonlimab allows the immune system to attack and kill cancer cells more effectively.
Approved indications
- Locally advanced or metastatic non-small cell lung cancer
- Locally advanced or metastatic small cell lung cancer
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Muscle or joint pain
- Rash
- Itching
- Hypothyroidism
- Increased liver enzymes
- Decreased white blood cell count
- Decreased platelet count
Key clinical trials
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) (PHASE1, PHASE2)
- Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) (PHASE2)
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) (PHASE1, PHASE2)
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study (PHASE3)
- Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) (PHASE1, PHASE2)
- Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) (PHASE1, PHASE2)
- Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) (PHASE1, PHASE2)
- Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pembrolizumab/Quavonlimab CI brief — competitive landscape report
- Pembrolizumab/Quavonlimab updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI